BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:RBD5044 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of RBD5044\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07587788-1088@assetmemo.bio
DTSTAMP:20261121T005815Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:RBD5044: Phase 2 readout est. (NCT07587788)
DESCRIPTION:RBD5044\, phase 2\, Hypertriglyceridemia.\nStudy: RBD5044 in Ch
 inese Participants With Hypertriglyceridemia\nEstimated primary completion
 : March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rbd5044
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 87788
URL:https://assetmemo.bio/drug/rbd5044#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797401-1088@assetmemo.bio
DTSTAMP:20261121T005815Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:RBD5044: Phase 2 readout est. (NCT06797401)
DESCRIPTION:RBD5044\, phase 2\, Hypertriglyceridemia.\nStudy: Phase 2 Trial
  Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dysl
 ipidemia\nEstimated primary completion: 31 May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rbd5044#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06797401
URL:https://assetmemo.bio/drug/rbd5044#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
